Global Partners LP
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLP research report →
Range $46 – $46
Price Chart
About the company
Global Partners LP engages in the purchasing, selling, gathering, blending, storing, and logistics of transporting gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, and propane to wholesalers, retailers, and commercial customers. The company operates through three segments: Wholesale, Gasoline Distribution and Station Operations (GDSO), and Commercial. The Wholesale segment sells home heating oil, branded and unbranded gasoline and gasoline blendstocks, diesel, kerosene, and residual oil to retailers and wholesale distributors.
- CEO
- Eric Slifka
- IPO
- 2005
- Employees
- 4,700
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on GLP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.58B
- P/E
- 9.42
- Fwd P/E
- 7.91
- PEG
- 0.11
- P/S
- 0.07
- P/B
- 2.12
- EV/EBITDA
- 8.77
- Div Yield
- 6.59%
- Gross Margin
- 5.92%
- Op Margin
- 2.50%
- Net Margin
- 0.80%
- ROE
- 24.61%
- ROIC
- 17.53%
Latest fiscal year · YoY change
- Revenue
- $18.56B+8.1%
- Gross Profit
- $491.62M-53.5%
- Op Income
- $191.28M
- Net Income
- $79.22M-26.4%
- EPS
- $2.13-13.1%
- OCF Growth
- +801.3%
- FCF Growth
- +167.4%
- 52W High
- $54.29
- 52W Low
- $39.58
- 50D MA
- $49.96
- 200D MA
- $47.43
- Beta
- 1.05
- RSI (14)
- 33
- Avg Volume
- 70.48K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Global Partners posted sharply higher Q2 results on stronger fuel margins, while maintaining solid coverage and continuing to return capital through its distribution and preferred unit redemption.· August 7, 2026
- Net income rose to $71 million from $25.2 million a year ago; EBITDA increased to $146 million from $95.7 million and adjusted EBITDA to $148.2 million from $98.2 million.
- GDSO drove the quarter, with product margin up $37.3 million to $245.2 million and gasoline fuel margin rising to $0.50/gal from $0.36/gal.
- Wholesale product margin rose to $106.5 million and commercial product margin increased to $10.5 million, helped by more favorable gasoline and bunkering conditions.
- Distribution coverage remained healthy at 2.25x, or 2.19x including preferred distributions.
- Management raised the quarterly common distribution to $0.78 per unit and redeemed all outstanding Series B fixed-rate preferred units on July 30.
Q2 2026 net income was $71 million versus $25.2 million in Q2 2025. EBITDA was $146 million versus $95.7 million, adjusted EBITDA was $148.2 million versus $98.2 million, distributable cash flow was $92.6 million versus $52 million, and adjusted DCF was $92.5 million versus $52.3 million. GDSO product margin increased $37.3 million to $245.2 million, including gasoline distribution margin up $37.1 million to $175 million and fuel margin rising to $0.50 per gallon from $0.36. Wholesale product margin increased $14.8 million to $106.5 million, and commercial product margin increased $4.4 million to $10.5 million. Operating expenses were $136.8 million, SG&A was $83 million, and interest expense was $33.1 million. CapEx was $35 million in the quarter, including $15.9 million maintenance and $19.1 million expansion. For full-year 2026, maintenance CapEx is expected at $60 million to $70 million and expansion CapEx excluding acquisitions at $75 million to $85 million. Leverage was 2.85x at June 30, with $174.6 million outstanding on the working capital revolver and $103.5 million outstanding on the revolving credit facility. The board approved a quarterly cash distribution of $0.78 per common unit, or $3.12 annualized.
Eric Slifka said the quarter showed the strength of Global’s integrated liquid energy platform and diversification across products, markets, and customers. He emphasized that the company’s model can generate steady cash flow while also capturing upside when markets are dynamic, and said the balance sheet and asset base position Global well for the rest of 2026 and beyond. On capital allocation, he reiterated a focus on investing thoughtfully and targeting the highest-return opportunities.
Gregory Hanson highlighted that the quarter benefited from strong year-over-year margin improvement across segments and that coverage remained strong at 2.25x, or 2.19x including preferred distributions. He noted that operating expenses rose modestly and SG&A increased to $83 million mainly from incentive comp, wages, and benefits, while interest expense fell to $33.1 million due partly to lower average credit facility balances. He also pointed to a strong balance sheet, 2.85x leverage, ample bank capacity, and said redeeming the Series B preferred units was accretive and simplified the capital structure.
Analysts asked whether higher prices were affecting consumer behavior, and management said they are seeing only a slight impact: smaller fill-ups and some trading down from 93 octane to 87 octane, but nothing material in store sales or transactions, including through the first month of Q3. On the preferred redemption, management said it was driven by the 9.5% fixed cost, strong year-to-date excess cash flow, and a desire to simplify the capital structure, while still leaving open the possibility of using pref or equity for future acquisitions. On M&A, Eric Slifka said the deal environment is busy and that Global will pursue assets that fit its platform and where it can be the high bidder.
The bull case is that Global is showing it can perform across a volatile market, with sharp margin gains in GDSO and solid contributions from wholesale and commercial. Management also signaled strong financial flexibility through healthy coverage, low leverage, excess bank capacity, and an accretive preferred redemption that reduces complexity.
The main risks discussed were volatile refined product markets, steep backwardation that could raise inventory carrying costs, and ongoing inventory risk tied to price swings. Management also acknowledged some inflation-related consumer pressure, with slightly smaller fill-ups and modest trading down, even if it was not material in the quarter.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.1%
- Shares Outstanding
- 33.97M
- Float Shares
- 27.56M
of shares held by institutions
109 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for GLP, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Mark E. GreenHouse · TN07 | Sell | Oct 6, 21 | Filing → |
| Mark E. GreenHouse · TN07 | Sell | Oct 5, 21 | Filing → |
| Mark E. GreenHouse · TN07 | Buy | Sep 24, 21 | Filing → |
| Mark E. GreenHouse · TN07 | Buy | Sep 23, 21 | Filing → |
| Mark E. GreenHouse · TN07 | Buy | Sep 2, 21 | Filing → |
| Mark E. GreenHouse · TN07 | Buy | Sep 1, 21 | Filing → |
| Mark E. GreenHouse · TN07 | Sell | May 7, 21 | Filing → |
| Mark E. GreenHouse · TN07 | Buy | Apr 15, 21 | Filing → |
| Mark E. GreenHouse · TN07 | Sell | Aug 14, 20 | Filing → |
| Mark E. GreenHouse · TN07 | Sell | Aug 11, 20 | Filing → |
| Mark E. GreenHouse · TN07 | Buy | Aug 4, 20 | Filing → |
| Mark E. GreenHouse · TN07 | Buy | Aug 6, 20 | Filing → |
| Mark E. GreenHouse · TN07 | Buy | Aug 4, 20 | Filing → |
| Mark E. GreenHouse · TN07 | Buy | Jul 2, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Alps Advisors Inc | 5.84M | ▼ 199.89K |
| Invesco Ltd. | 2.19M | 0 |
| Mirae Asset Global Etfs Holdings Ltd. | 2.06M | ▲ 24.12K |
| Pallas Capital Advisors LLC | 1.73M | ▲ 3.30K |
| Morgan Stanley | 702.12K | ▲ 190.61K |
| Goldman Sachs Group Inc | 639.88K | ▲ 4.59K |
| Jpmorgan Chase & Co | 582.48K | ▲ 68.06K |
| Kayne Anderson Capital Advisors LP | 285.48K | ▲ 253.56K |
| Blackstone Inc. | 230.01K | ▼ 10.70K |
| Royal Bank Of Canada | 224.78K | ▲ 47.62K |
| Fractal Investments LLC | 195.23K | 0 |
| Bank Of America Corp | 174.66K | ▲ 58.09K |
Held by 23 ETFs
Biggest fund positions in GLP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 21, 26 | Global GP LLC | buy | 5,000 |
| Sep 17, 26 | Global GP LLC | buy | 5,000 |
| Sep 16, 26 | Global GP LLC | buy | 5,000 |
| Sep 15, 26 | Global GP LLC | buy | 5,000 |
| Sep 14, 26 | Global GP LLC | buy | 5,000 |
| Jun 18, 26 | Global GP LLC | buy | 5,000 |
| Jun 17, 26 | Global GP LLC | buy | 5,000 |
| Jun 15, 26 | Global GP LLC | buy | 5,000 |
| Jun 12, 26 | Global GP LLC | buy | 5,000 |
| Jun 10, 26 | Global GP LLC | buy | 5,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GLP coverage
Recent articles, reports, and earnings notes.
No research on GLP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GLP report →Critical Analysis: Global Partners (NYSE:GLP) and EQT (NYSE:EQT)
defenseworld.net · Oct 5
MichaelAaron Flicker on How GLP-1s Change Food Industry & Household Dynamics
youtube.com · Oct 5
36,399 Shares of Global Partners LP $GLP Bought by Bank of America Corp DE
defenseworld.net · Oct 5
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
cnbc.com · Oct 2
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
globenewswire.com · Oct 1
Should Value Investors Buy Global Partners (GLP) Stock?
zacks.com · Oct 1
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
prnewswire.com · Oct 1
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
prnewswire.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.